FDA chides Boston on flawed record keeping during AAA stent trial
This article was originally published in Clinica
Executive Summary
Boston Scientific has received a rap on the knuckles by the FDA for its alleged inadequate reporting of unexpected adverse events - including patient deaths - that occurred during a clinical trial of a stent designed to treat abdominal aortic aneurysms (AAA).